Company intelligence / Profile preview

Inka Health

Canada

Ownership: Private
Development stage: Other

Overview

Inka Health developed and scaled an AI-driven platform for synthetic patient data and advanced causal analytics, primarily applied to oncology clinical trial acceleration and decision support. The company was acquired by Onco-Innovations in 2025 to enhance AI-powered precision oncology research, including simulation of clinical trials and generation of external control arms for rare and hard-to-treat cancers. Their flagship study involved AI-generated synthetic patient cohorts, published in September 2024, aimed at overcoming data scarcity in rare cancers and streamlining regulatory evidence generation.

Modalities: AI-driven analyticsSynthetic patient data models
Industry: Drug Discovery Services

Partnerships

AstraZeneca CanadaQuantify ResearchSubsaltOneMedNet

Beyond the preview

Go deeper on Inka Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inka Health.

Explore the full profile